Mealey's (May 18, 2021, 8:26 AM EDT) -- WASHINGTON, D.C. — The District of Columbia Circuit U.S. Court of Appeals on April 16 said the Food and Drug Administration erred when it classified a contrast agent as a drug and not a device, a ruling that sends the issue back to the FDA....